drugset / Trial / NCT05457010
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Timeline
- Start
- 2022-11-28
- Primary completion
- 2025-09-30
- Completion
- 2025-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARC-T Cells | Cell therapy | — | — |
| Subject | SPRX002 | Protein / enzyme biologic | — | — |